over 3 years ago • 2 mins
Roche, the world’s second-biggest pharmaceutical company, released a largely positive third-quarter update on Thursday – but investors found it a bitter pill to swallow 💊
Roche’s revenue would have come in 1% higher than the same time last year, but the rising value of its native Swiss currency reduced what overseas (and, indeed overland) sales were worth when brought back home. Revenue instead worked out 5% lower than a year ago – potentially rattling investors, who sent the company's stock down 3% 📉 Still, Roche’s du jour diagnostics business (which sells COVID-19 testing kits) continued to grow, with sales there up 2%. And even with the aforementioned “currency headwinds”, the firm confirmed it’ll rake in about as much this year as previously promised – which might bode well for rival diagnosticians Abbott Laboratories and acquisition-tastic Siemens Healthineers.
Diagnostics-focused pharma firms haven’t been investors’ number-one priority recently, given the understandable attention paid to Big Pharma’s attempts to develop a coronavirus vaccine 💉 But that laser focus has its drawbacks: fair-weather investors quickly grew skittish when companies like AstraZeneca (last month) and Johnson & Johnson and Eli Lilly (this week) announced pauses to clinical vaccine trials in response to patient illnesses. Temporary setbacks are par for the course with new treatments – but Eli Lilly’s 3% drop after its announcement suggests investors were hoping the drugmaker would follow a smoother path.
Drugstore chain Walgreens Boots Alliance announced stronger-than-predicted quarterly results on Thursday. That was partly thanks to the pandemic boosting sales of health and wellness items – including, perhaps, Stateside sales of Roche’s or rivals’ test kits 🦠 International revenue was a little queasier, however: sales fell as Boots stores were shuttered. Nevertheless, there was more good than bad – and Walgreens’ stock rose 3%.
Disclaimer: These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment advisor.